ES2527623T3 - Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus - Google Patents

Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus Download PDF

Info

Publication number
ES2527623T3
ES2527623T3 ES10814412.2T ES10814412T ES2527623T3 ES 2527623 T3 ES2527623 T3 ES 2527623T3 ES 10814412 T ES10814412 T ES 10814412T ES 2527623 T3 ES2527623 T3 ES 2527623T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
groups
formula
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10814412.2T
Other languages
English (en)
Spanish (es)
Inventor
Urban Ramstedt
Brennan Klose
Nicole Zitzmann
Raymond A. Dwek
Terry D. Butters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
United Therapeutics Corp
Original Assignee
University of Oxford
United Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford, United Therapeutics Corp filed Critical University of Oxford
Application granted granted Critical
Publication of ES2527623T3 publication Critical patent/ES2527623T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES10814412.2T 2009-09-04 2010-09-01 Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus Active ES2527623T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27225309P 2009-09-04 2009-09-04
US272253P 2009-09-04
US28250710P 2010-02-22 2010-02-22
US282507P 2010-02-22
PCT/US2010/047493 WO2011028779A1 (en) 2009-09-04 2010-09-01 Iminosugars and methods of treating filoviral diseases

Publications (1)

Publication Number Publication Date
ES2527623T3 true ES2527623T3 (es) 2015-01-27

Family

ID=43649618

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10814412.2T Active ES2527623T3 (es) 2009-09-04 2010-09-01 Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus

Country Status (8)

Country Link
US (1) US20110065754A1 (https=)
EP (1) EP2473046B1 (https=)
JP (1) JP5752689B2 (https=)
KR (1) KR20120081990A (https=)
CN (2) CN105748476A (https=)
CA (1) CA2772813A1 (https=)
ES (1) ES2527623T3 (https=)
WO (1) WO2011028779A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2398321B1 (en) 2009-02-23 2015-11-25 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
WO2013148791A1 (en) 2012-03-28 2013-10-03 Institute For Hepatitis And Virus Research Novel alkylated imino sugars exhibiting glucosidase inhibition and their method of use
KR20150035767A (ko) 2012-06-06 2015-04-07 유니터 바이롤로지, 엘엘씨 신규 이미노당 및 그의 용도
CN106102464A (zh) * 2013-05-02 2016-11-09 牛津大学之校长及学者 采用亚氨基糖的糖脂抑制
JP6456393B2 (ja) 2013-09-16 2019-01-23 エマージェント バイロロジー エルエルシー デオキシノジリマイシン誘導体およびその使用方法
EP3200826B1 (en) * 2014-09-30 2021-04-21 Vecht-lifshitz, Susan Eve Pharmaceutical compositions for treating ebola virus disease
BR112017008898B1 (pt) 2014-11-05 2022-11-29 Emergent Virology Llc Compostos de iminoaçúcares, suas composições farmacêuticas e usos dos mesmos para tratar doenças virais
CN109628647A (zh) * 2019-02-02 2019-04-16 广州市妇女儿童医疗中心 抗病毒药物筛选方法及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2834122A1 (de) 1978-08-03 1980-02-14 Bayer Ag Verfahren zur herstellung von 6-amino-6-desoxy-l-sorbose
DE2839309A1 (de) * 1978-09-09 1980-03-27 Bayer Ag 3,4,5-trihydroxypiperidin-derivate
DE2853573A1 (de) 1978-12-12 1980-07-03 Bayer Ag Herstellung von n-substituierten derivaten des l-desoxynojirimycins
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
DE3611841A1 (de) * 1986-04-09 1987-10-15 Bayer Ag Verfahren zur herstellung von 1-desoxynojirimycin und dessen n-derivaten
US5043273A (en) * 1989-08-17 1991-08-27 Monsanto Company Phosphorylated glycosidase inhibitor prodrugs
US5103008A (en) * 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US4994572A (en) * 1989-10-12 1991-02-19 Monsanto Company Synthesis of nojirimycin derivatives
US5030638A (en) * 1990-02-26 1991-07-09 G. D. Searle & Co. Method of antiviral enhancement
US5200523A (en) * 1990-10-10 1993-04-06 Monsanto Company Synthesis of nojirimycin derivatives
ZA931934B (en) 1992-03-18 1993-03-18 Us Bioscience Compostitions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
US5206251A (en) * 1992-04-01 1993-04-27 G. D. Searle & Co. 2- and 3- amino and azido derivatives of 1,5-iminosugars
US5399567A (en) * 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
AU1876095A (en) 1994-02-25 1995-09-11 G.D. Searle & Co. Use of 1-deoxynojirimycin and its derivatives for treating mammals infected with respiratory syncytial virus
KR20010033028A (ko) 1997-12-11 2001-04-25 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 막-관련 바이러스 복제의 억제
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6610703B1 (en) * 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB9828474D0 (en) * 1998-12-24 1999-02-17 British Aerospace Surface topology inspection
ATE402701T1 (de) * 1999-02-12 2008-08-15 United Therapeutics Corp N-(8,8,8-trifluorooctyl)-1,5-dideoxy-1,5-imino- - glucitol zur behandlung von hepatitis-virus- infektionen
GB0100889D0 (en) * 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
EP1196190B1 (en) * 1999-07-26 2003-03-19 G.D. SEARLE & CO. Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases
US7256005B2 (en) * 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
EP2857036B1 (en) * 2003-01-31 2016-12-21 Mount Sinai School of Medicine of New York University Combination therapy for treating protein deficiency disorders
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20050256168A1 (en) * 2004-04-28 2005-11-17 Block Timothy M Compositions for oral administration for the treatment of interferon-responsive disorders
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
GB0501352D0 (en) * 2005-01-21 2005-03-02 Slingsby Jason H Use of glycosylation modulators in combination with membrane fusion inhibitors for treatment of infections caused by viruses bearing glycosylated envelope
CA2601797A1 (en) * 2005-03-16 2006-09-21 University Of Oxford Mannose immunogens for hiv-1
EP3782655A1 (en) * 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용
US20100004156A1 (en) * 2005-07-27 2010-01-07 Shalesh Kaushal Small Compounds That Correct Protein Misfolding and Uses Thereof
US20070244184A1 (en) * 2006-01-09 2007-10-18 Simon Fraser University Glycosidase inhibitors and methods of synthesizing same
DE602007008870D1 (de) * 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
CN104876855A (zh) * 2006-05-24 2015-09-02 联合治疗公司 脱氧吉瑞霉素和d-阿拉伯胶素醇类似物及使用方法
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
KR20090057035A (ko) * 2006-08-21 2009-06-03 유나이티드 세러퓨틱스 코오포레이션 바이러스 감염의 치료를 위한 병용 요법
KR20100127842A (ko) * 2008-03-26 2010-12-06 유니버시티 오브 옥스퍼드 소포체 표적화 리포좀
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
US8703744B2 (en) * 2009-03-27 2014-04-22 The Chancellor, Masters And Scholars Of The University Of Oxford Cholesterol level lowering liposomes

Also Published As

Publication number Publication date
JP2013503881A (ja) 2013-02-04
KR20120081990A (ko) 2012-07-20
EP2473046A1 (en) 2012-07-11
EP2473046B1 (en) 2014-10-22
US20110065754A1 (en) 2011-03-17
CN105748476A (zh) 2016-07-13
JP5752689B2 (ja) 2015-07-22
CA2772813A1 (en) 2011-03-10
EP2473046A4 (en) 2013-04-24
WO2011028779A1 (en) 2011-03-10
CN102595895A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
ES2527623T3 (es) Iminoazúcares para su uso en el tratamiento de enfermedades por filovirus
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
AR116395A2 (es) 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida, su monohidrato o sal en una forma de pureza alta
UY32062A (es) Inhibidores de beta-secretasa
UY32490A (es) Inhibidores de beta-secretasa
UY30437A1 (es) Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
ECSP077648A (es) Tetrazolilos macrociclicos como inhibidores de serina proteasa de hepatitis c
ES2531009T3 (es) Análogos sustituidos de dicetopiperazina para su uso como agentes para la administración de fármacos
ECSP077649A (es) Piridazinonilos macrociclicos como inhibidores de serina proteasa de hepatitis c
AR068045A1 (es) Derivados de catecolamina y prodrogas de los mismos
CO6230986A2 (es) Compuesto de 4-piridinona y su uso para cancer
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
PA8785401A1 (es) Derivados de bencimidazol
CY1111934T1 (el) Σταθεροποιημενες φαρμακευτικες συνθεσεις οι οποιες περιεχουν φεσοτεροδινη
UY30392A1 (es) Compuestos de oximilo macrociclico inhibidores de proteasa de hepatitis c
EA201100795A1 (ru) Фармацевтическая композиция эффективного ингибитора всг для перорального введения
BR112013028487A2 (pt) inibidores do vírus da hepatite c
UY30391A1 (es) Compuesto de oximilo aciclico inhibidores de proteasa de hepatitis c
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
CR20130054A (es) Procesos para preparar compuestos antivirales
BR112013032049A2 (pt) inibidores do vírus da hepatite c
AR059619A1 (es) Derivados halogenados de sulfonamidas
CR20110524A (es) Proceso para preparar compuestos antivirales
GT200600039A (es) Tiazolidinonas, su preparacion y su uso como medicamento
ES2531159T3 (es) Compuestos y métodos para el tratamiento del cáncer